ArticleThe Journal of experimental medicine1999
Identification of CD22 ligands on bone marrow sinusoidal endothelium implicated in CD22-dependent homing of recirculating B cells.
Article in The Journal of experimental medicine, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 113 citations in OpenAlex.
- Discovery and characterization of vertebrate sialoglycan-binding proteins.Seminars in immunology · 2025Review
- Siglec-6 as a therapeutic target for cell migration and adhesion in chronic lymphocytic leukemia.Nature communications · 2024Article
- The Role of the Transcriptional Coactivator BOB.1/OBF.1 in Adaptive Immunity.Advances in experimental medicine and biology · 2024Review
- The role ofFrontiers in immunology · 2023Review
- Sugar-decorated carbon dots: a novel tool for targeting immunomodulatory receptors.Nanoscale advances · 2022Article
- T-bet+ Memory B Cells Link to Local Cross-Reactive IgG upon Human Rhinovirus Infection.Cell reports · 2020Article
- Coordinated roles for glycans in regulating the inhibitory function of CD22 on B cells.Biomedical journal · 2019Review
- Targeting B Cells and Plasma Cells in Autoimmune Diseases.Frontiers in immunology · 2018Review
- CD22: A Regulator of Innate and Adaptive B Cell Responses and Autoimmunity.Frontiers in immunology · 2018Review
- Human CD22 Inhibits Murine B Cell Receptor Activation in a Human CD22 Transgenic Mouse Model.Journal of immunology (Baltimore, Md. : 1950) · 2017Article
- Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling.Arthritis research & therapy · 2017Article
- Viewing Siglecs through the lens of tumor immunology.Immunological reviews · 2017Review
- Article
- Unmasking of CD22 Co-receptor on Germinal Center B-cells Occurs by Alternative Mechanisms in Mouse and Man.The Journal of biological chemistry · 2015Article
- Interaction of platelet endothelial cell adhesion molecule (PECAM) with α2,6-sialylated glycan regulates its cell surface residency and anti-apoptotic role.The Journal of biological chemistry · 2014Article
- High endothelial venules through a transcriptomics lens.Nature immunology · 2014Article
- Transcriptional programs of lymphoid tissue capillary and high endothelium reveal control mechanisms for lymphocyte homing.Nature immunology · 2014Article
- CD22 ligand-binding and signaling domains reciprocally regulate B-cell Ca2+ signaling.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models.The Journal of clinical investigation · 2013Article
- CD22 is required for protection against West Nile virus Infection.Journal of virology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
Abstract
CD22 is a B cell-specific transmembrane protein known to function as a negative regulator of B cell signaling. It has also been implicated in cell adhesion through recognition of alpha2,6-linked sialic acids on glycans of target cells. Previous studies showed that CD22-deficient mice had a strongly reduced population of mature recirculating B cells in the bone marrow despite normal B cell development. Using a soluble recombinant form of the receptor (CD22-Fc), we demonstrate here that sialylated ligands for CD22 are expressed on sinusoidal endothelial cells of murine bone marrow but not on endothelial cells in other tissues examined. Injection of CD22-Fc revealed that the CD22 ligands in the bone marrow were accessible to the circulation. Treatment of mice with either CD22-Fc or affinity-purified anti-CD22 antibody led to an approximately 50% reduction in mature recirculating B cells in the bone marrow without affecting numbers in the spleen. Finally, consistent with the notion that CD22 is a homing receptor, we show that compared with wild-type mice, CD22-deficient animals have a lower number of immunoglobulin M-secreting plasma cells in the bone marrow.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.